Theratechnologies Receives FDA Agreement To Amended Trial Protocol For Its Lead PDC Candidate Sudocetaxel Zendusortide
Portfolio Pulse from Happy Mohamed
Theratechnologies has received FDA approval for its amended Phase 1 trial protocol for sudocetaxel zendusortide, a peptide-drug conjugate targeting the sortilin receptor in cancer cells. The trial will now focus on patients with ovarian cancer and refined patient selection.
June 02, 2023 | 4:18 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Theratechnologies receives FDA approval for its amended Phase 1 trial protocol for sudocetaxel zendusortide, potentially expediting the development of this novel cancer therapy.
The FDA approval of the amended Phase 1 trial protocol for sudocetaxel zendusortide is a positive development for Theratechnologies. This approval allows the company to resume the trial, focusing on patients with ovarian cancer and refined patient selection. The successful development and eventual commercialization of sudocetaxel zendusortide could have a significant impact on the company's revenues and growth prospects, making this news likely to have a positive short-term impact on THTX stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100